Skip to main
IBIO

iBio (IBIO) Stock Forecast & Price Target

iBio (IBIO) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

iBio Inc. has positioned itself favorably in the biotechnology sector by leveraging Artificial Intelligence for the development of precision antibodies, thereby minimizing downstream development risks through its innovative technology stack. The company's focus on optimizing candidates for manufacturability and subcutaneous administration enhances its potential for successful clinical outcomes, which is underscored by the strong early data surrounding comparative therapies like Winrevair. Furthermore, iBio's commitment to addressing critical health challenges, such as obesity and metabolic diseases, aligns with growing market demands, positioning the company for potential growth in a competitive landscape.

Bears say

The analysis indicates that iBio Inc faces significant risks related to the potential obsolescence of its therapies due to the development of new treatment methods for targeted diseases. There are also concerns regarding the outcomes of current and future phase I/II/III clinical trials, which could exert downward pressure on the stock if the results fail to meet regulatory expectations or clinical endpoints. Furthermore, uncertainties surrounding the protection of key intellectual property pose an additional threat to the company's competitive position and financial stability.

iBio (IBIO) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iBio (IBIO) Forecast

Analysts have given iBio (IBIO) a Buy based on their latest research and market trends.

According to 4 analysts, iBio (IBIO) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iBio (IBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.